TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced it will host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific and clinical updates across its development pipeline. The presentation will be anchored by the company’s recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer and will also include portfolio updates and discussion of its broader investment thesis.
The webcast marks a significant milestone for the clinical-stage company, which is pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. According to the press release, the company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. The Phase 2a trial represents a critical step in validating this approach for patients with colorectal cancer, a disease that remains a leading cause of cancer-related deaths worldwide.
For investors and industry observers, this webcast offers a rare opportunity to delve into the science behind TransCode’s pipeline and assess the potential of its therapeutic candidates. The company’s portfolio includes other first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells. The webcast could provide clarity on how these candidates fit into the broader landscape of cancer immunotherapy and RNA-based treatments.
The announcement is particularly important given the high unmet need in metastatic colorectal cancer. Current treatment options often have limited efficacy, and the targeting of microRNA-10b, which is associated with metastasis, represents a novel approach. If successful, TTX-MC138 could offer a new therapeutic option for patients with advanced disease. The Phase 2a trial’s focus on circulating tumor DNA-positive patients suggests a precision medicine strategy, potentially identifying those most likely to benefit.
TransCode’s decision to host the webcast publicly also signals a commitment to transparency and investor communication. For stakeholders, the event could influence perceptions of the company’s value and future prospects. The broader implications extend to the field of RNA therapeutics, which has gained traction following the success of mRNA vaccines. TransCode’s work on microRNA-targeting therapies could further validate this platform and open doors for other indications.
For more details, the full press release is available at https://ibn.fm/u5AfW. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
